Skip to main content

Table 2 Pooled HCC incidence in CHB patients receiving different treatments via the meta-analysis

From: Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Treatment

Cumulative incidence (%, 95 CI)

Incidence density (per 100 persons-year, 95% CI)

≤3 years

3-4 years

4-5 years

>5 years

Total patients

 ETV

4.08 (0.88-9.03)

5.81 (3.52-8.61)

6.55 (4.84-8.49)

8.24 (7.34-9.18)

1.43 (1.14-1.75)

 TDF

3.16 (1.12-6.14)

3.65 (2.21-5.42)

7.12 (5.97-8.37)

NEa

1.07 (0.74-1.46)

 Other NAs

10.34 (6.60-14.78)

11.11 (4.35-20.23)

13.04 (1.81-30.45)

12.61 (11.22-14.07)

2.84 (1.86-4.00)

Patient with preexisting cirrhosis

 ETV

5.01 (1.32-10.49)

10.16 (6.91-13.93)

11.71 (10.72-12.73)

14.21 (10.87-17.91)

2.78 (2.21-3.40)

 TDF

NA

7.76 (5.46-10.42)

12.48 (5.86-21.11)

NA

2.59 (1.51-3.96)

 Other NAs

10.34 (6.60-14.78)

NA

21.28 (18.61-24.08)

24.49 (13.33-37.62)

4.81 (3.36-6.49)

Patient without preexisting cirrhosis

 ETV

0.66 (0.19-1.38)

1.79 (1.05-2.69)

2.78 (1.49-4.44)

3.04 (2.05-4.21)

0.49 (0.32-0.68)

 TDF

0.09 (0.02-0.20)

NA

2.26 (1.17-3.68)

NA

0.30 (0.06-0.70)

 Other NAs

NA

NA

NA

4.54 (3.31-5.94)

0.78 (0.56-1.02)

  1. CI confidence interval, NA not available, NE not estimated
  2. aOnly one study contributed to these data, and none of the patient developed HCC during the follow-up
  3. *If heterogeneity was greater than 50%, the results of the random effects model are reported in the table; otherwise, the results of the fixed effects model are reported